In a test of 66 patients with the blood disease multiple myeloma, a full 100 percent of the subjects saw their cancer reduced by half.
66名患有多发性骨髓瘤(一种血液系统疾病)的患者参与了此项药物试验，结果所有患者的癌灶都缩减了一半。
Revlimid, which is approved for multiple myeloma patients in combination with the steroid dexamethasone, and for a rare condition called myelodysplastic syndromes, had revenue of $1.7 billion in 2009.
Revlimid和类固醇地塞米松联合用药被批准用于多发性脊髓瘤和罕见病骨髓增生异常综合征 的治疗。 其2009年的销售额为17亿美元。
There are "trends" -- subtle increases -- in gastro-esophageal cancers and blood cancers such as multiple myeloma, and non-Hodgkin's lymphoma, said Prezant, but they are difficult to generalize.
食道癌，多发性肿瘤性血癌，非霍奇金淋巴瘤等癌症在“趋势”上有微妙的增加。但很难加以概括，Prezant说。
Q: When you first developed symptoms of multiple myeloma, you were disappointed to find that available research was not very helpful in deciding what to do.
问：当你最早发现自己出现多发性骨髓瘤症状时，却失望地发现现有研究对如何治疗的决定并无多大帮助。
Now entering my fifth year of living with multiple myeloma, a haematological cancer, I reflect back on a roller-coaster ride of symptoms, treatments and side effects.
今年是我患上多发性骨髓瘤的第五个年头，这是一种血癌，我回顾了一下患上此病后的一系列突变的症状、治疗以及副作用。
The researchers deployed a combination of peptides—small pieces of protein—that are known to be specific to multiple myeloma cells and are important for their survival.
这些研究人员将肽（蛋白质片段）化合物作为研究重点，该化合物为多发性骨髓瘤细胞所独有，对于这种细胞的生存至关重要。
Primary amyloidosis isn't associated with other diseases - except for multiple myeloma, a form of bone marrow cancer.
原发性淀粉样变通常不伴有其他疾病——骨髓肉瘤(一种骨髓恶性肿瘤)除外。
Multiple myeloma is a blood cancer that typically strikes much later in life.
多发性肿瘤是一种血癌，通常在晚期才发作。
George Vlasuk, chief executive of Sirtris, said in a phone interview that the complication is common in multiple myeloma patients and "may or may not be related to" the drug.
Sirtris的首席执行官George Vlasuk在一个电话采访中说并发症对于多发性骨髓瘤很普遍，“可能会也可能不会”是和药物有关。
Research funded by the multiple myeloma Re — search Foundation at a small biotech led to a promising new drug for multiple myeloma, a cancer of plasma cells in bones.
Multiple Myeloma研究基金会资助了一家小型生物科技企业的研究，发现了一种很有前途的新药，能够治疗多发性骨髓瘤，一种骨头中原生质细胞的癌症。
Objective To investigate the clinical features in patients with multiple myeloma (MM) and the significance of bone marrow cell morphology in MM diagnosis.
目的：探讨多发性骨髓瘤(MM)的主要临床特点以及骨髓细胞形态学在MM诊断中的作用。
In January, two thousand two, doctors discovered that Eppie Lederer had multiple myeloma. It is a very serious form of cancer of the bone marrow.
2002年1月，医生发现艾比.莱德尔身患严重的骨髓瘤，这是生长于骨髓中一种非常严重的癌症，六个月后，即2002年6月22日，艾比.德尔去逝，享年83岁。
At low power, the abnormal plasma cells of multiple myeloma fill the marrow.
低倍镜显示多发性骨髓瘤异常浆细胞弥漫浸润骨髓。
The skull demonstrates the characteristic rounded "punched out" lesions of multiple myeloma.
颅骨显示多发性骨髓瘤典型的圆形“打孔样”病损。
"We already know that the over-expression or mutation of molecules known as NIK and TRAF3 in B cells is associated with human multiple myeloma," said Professor Mackay.
“我们已经知道，在B细胞过度表达或突变的NIK和TRAF3分子是与人类多发性骨髓瘤相关，”麦凯教授说。
Multiple myeloma gene expression data was analyzed and Self Organization Prediction Model (SOPM) based on Self-Organization Mapping (SOM) networks was established for predicting multiple myeloma.
本研究基于自组织映射网络(SOM)，分析多骨髓瘤基因表达数据，建立预测多骨髓瘤的自组织预测模型(SOPM)。
At medium power, the plasma cells of multiple myeloma here are very similar to normal plasma cells, but they may also be poorly differentiated.
中倍镜显示多发性骨髓瘤的浆细胞与正常浆细胞很相似，但分化较差。
Methods Three-colour direct immunofluorescence staining and multiparameter flow cytometry were used for analysis of 13 samples of immunophenotyping of multiple myeloma patients.
方法采用三色免疫荧光直接标记法及多参数流式细胞术分析13例多发性骨髓瘤的免疫表型。
Objective: To observe the function and nursing of treating ostealgia induced by multiple myeloma with Micalcic.
目的：观察密盖息在治疗多发性骨髓瘤疼痛中的作用和总结护理体会。
The lesson to be learned from the present case is that a transient plasma cell dyscrasia may present like multiple myeloma in the setting of heavy immunosuppression after organ transplantation.
从这个病例中得到的教训是，在器官移植后的严重免疫抑制状况下，暂时性血细胞恶液质可以有类似多发性骨髓瘤样的表现。
Objective to estimate the prevalence of depression and anxiety in patients with multiple myeloma (MM) and to analyze the possible impact factors.
目的评估多发性骨髓瘤(MM)患者伴抑郁、焦虑情绪的发生率，并分析其相关的影响因素。
Objective: To explore the clinical and laboratory features of multiple myeloma(MM) .
目的：研究多发性骨髓瘤（MM）的临床及实验室特征。
Objective To observe the therapeutic efficacy and safety of donor leukocyte infusion (DLI) in acute, chronic leukemia and multiple myeloma.
目的观察供体白细胞输注(DL I)治疗急慢性白血病和多发性骨髓瘤的疗效和安全性。
Their findings may one day help in the development of targeted therapies for leukemia, multiple myeloma and other cancers of the blood.
这一发现有助于开发靶向治疗白血病、多发性骨髓瘤以及其他血癌的药物。
Purpose to assess the impact of age on outcome and to analyze the projected years of life lost in patients with multiple myeloma.
目的：评估多发性骨髓瘤患者年龄对生存结果的影响并分析其特殊的损失寿命年。
ObjectiveTo explore the specific locus deletion of the long arm of chromosome 13 and its relationship with the clinical behavior and prognosis of multiple myeloma (MM).
目的研究多发性骨髓瘤(MM)患者13号染色体长臂特定位点的缺失及与临床表现、预后的关系。
Objective: To explore foreseeable nursing intervention in the treatment of elderly multiple myeloma combined with thoracic and lumber vertebrae fracture.
目的：探讨预见性护理干预在老年性多发性骨髓瘤合并胸腰椎骨折患者护理中的应用和效果。
Objective to investigate the efficacy and toxicity of bortezomib in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (MM).
目的观察硼替佐米联合地塞米松治疗复发、难治性多发性骨髓瘤(MM)患者的疗效和不良反应。
Conclusion: Proliferation of bone marrow plasmacyte and the quantity or urine Bence-Jones protein are main causes of kidney lesion in multiple myeloma.
结论：骨髓浆细胞增殖及尿链蛋白产生可能是多发性骨髓瘤肾脏损害的主要原因。
Conclusion: Proliferation of bone marrow plasmacyte and the quantity or urine Bence-Jones protein are main causes of kidney lesion in multiple myeloma.
结论：骨髓浆细胞增殖及尿链蛋白产生可能是多发性骨髓瘤肾脏损害的主要原因。
应用推荐